Treatment plan
Agents and doses/routes . | Schedule . |
---|---|
R-CDE | |
Rituximab, 375 mg/m2 | Every 28 d just before the initiation of each cycle of CDE |
Cyclophosphamide, 187.5-200 mg/m2/d for 4 d* | Repeat every 28 d for a maximum of 6 cycles |
Doxorubicin, 12.5 mg/m2/d for 4 d* | |
Etoposide, 60 mg/m2/d for 4 d, continuous intravenous infusion over 96 h | |
Colony-stimulating factor filgrastim (G-CSF), 5 μg/kg/d, subcutaneous injection | D 6 until neutrophil recovery |
Infection prophylaxis required | |
Trimethoprim-sulfamethoxazole, 160 mg/800 mg by mouth | 3 times/wk |
Fluconazole, 100 mg by mouth | Daily |
Central nervous system prophylaxis | |
Intrathecal methotrexate, 12 mg | D 1 of each cycle (n = 68) |
OR | |
Intrathecal cytarabine, 50 mg | D 1 and 4 of cycles 1 and 2 for patients with Burkitt lymphoma or bone marrow involvement only (n = 6) |
Agents and doses/routes . | Schedule . |
---|---|
R-CDE | |
Rituximab, 375 mg/m2 | Every 28 d just before the initiation of each cycle of CDE |
Cyclophosphamide, 187.5-200 mg/m2/d for 4 d* | Repeat every 28 d for a maximum of 6 cycles |
Doxorubicin, 12.5 mg/m2/d for 4 d* | |
Etoposide, 60 mg/m2/d for 4 d, continuous intravenous infusion over 96 h | |
Colony-stimulating factor filgrastim (G-CSF), 5 μg/kg/d, subcutaneous injection | D 6 until neutrophil recovery |
Infection prophylaxis required | |
Trimethoprim-sulfamethoxazole, 160 mg/800 mg by mouth | 3 times/wk |
Fluconazole, 100 mg by mouth | Daily |
Central nervous system prophylaxis | |
Intrathecal methotrexate, 12 mg | D 1 of each cycle (n = 68) |
OR | |
Intrathecal cytarabine, 50 mg | D 1 and 4 of cycles 1 and 2 for patients with Burkitt lymphoma or bone marrow involvement only (n = 6) |
The daily dose of cyclophosphamide and doxorubicin was admixed in the same bag of intravenous fluid (1 L) and was infused through a central venous catheter, and etoposide was diluted in a separate liter of intravenous fluid and infused through a separate central venous catheter or peripheral line.